SynthesisCardiovascular therapeutics2019
Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis.
Synthesis in Cardiovascular therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 15 registered trials, which are not on this map. Cited by 28 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Ticagrelor Versus Clopidogrel in Ischemic Stroke. a Randomized Double-blinded Controlled Trial
Ticagrelor Versus Clopidogrel in Large Vessel Ischemic Stroke, a Randomized Controlled Trial
Ticagrelor Versus Cilostazol in Ischemic Stroke
Clopidogrel Versus Cilostazol in Ischemic Stroke, a Randomized Controlled Trial
Clopidogrel Versus Cilostazol in Large-vessel Ischemic Stroke, a Randomized Controlled Trial
Concomitant Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Small Vessel Stroke, a Randomized Controlled Single-blinded Trial
Combining Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Large-vessel Ischemic Stroke, a Randomized Controlled Single-blinded Trial
Rivaroxaban Versus Apixaban in Cerebral Venous Thrombosis, a Randomized Controlled Trial
Dabigatran Versus Rivaroxaban in Cerebral Venous Thrombosis, a Randomized Controlled Trial
Dabigatran Versus Apixaban in Cerebral Venous Thrombosis, a Randomized Controlled Trial
Ticagrelor Versus Cilostazol in Moderate and Moderate-to-severe Ischemic Stroke, a Randomized Controlled Trial
Combining Aspirin With Cilostazol or Clopidogrel in Minor Stroke or TIA, a Randomized Controlled Trial
Combining Aspirin With Ticagrelor or Clopidogrel in Large-vessel Minor Stroke or TIA, a Randomized Controlled Trial
Combining Aspirin With Ticagrelor or Cilostazol in Large-vessel Minor Stroke or TIA, a Randomized Controlled Trial
The Safety and Efficacy of Acetyl-leucine in Post-stroke Ataxia: a Randomized Placebo-controlled Trial
Who cites it
28 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Comparison of P2Y12 inhibitors and aspirin in secondary prevention of coronary events: a meta-analysis of RCTs.BMC cardiovascular disorders · 2025Pooled it
- Tailoring dual antiplatelet therapy for stroke prevention: a meta-analysis of timing, duration, regimen, and stroke subtypes.Frontiers in pharmacology · 2025Pooled it
- The Efficacy and Safety of Cilostazol vs. Aspirin for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis.Frontiers in neurology · 2022Pooled it
- The Impact of Preinjury Use of Antiplatelet Drugs on Outcomes of Traumatic Brain Injury: A Systematic Review and Meta-Analysis.Frontiers in neurology · 2022Pooled it
- A new first line choice? Has clopidogrel superseded aspirin for secondary prevention following selected minor ischaemic strokes?Internal medicine journal · 2026Article
- Arterial Thrombosis in Severe Ulcerative Colitis: A Case-Based Narrative Review of Current Evidence.Biomedicines · 2026Review
- Clinical outcomes of a generic versus brand-name clopidogrel for secondary prevention in patients with ischemic stroke: a nationwide retrospective cohort study.BMC neurology · 2026Article
- Analysis of Treatment Pattern of Antiplatelet in First-Ever Ischemic Stroke Without Previous Antiplatelet Use: A Real-World Distributed Network Analysis of 11 Observational Korean Databases Using a Common Data Model.Journal of Korean medical science · 2025Observational
- Comparative Effectiveness of Clopidogrel Versus Aspirin for Primary Prevention in High-Risk Patients with Type 2 Diabetes: A Nationwide Propensity Score-Matched Cohort Study.Medicina (Kaunas, Lithuania) · 2025Article
- Clopidogrel May Be Superior to Aspirin as Maintenance Antiplatelet Monotherapy in Patients With Non-Cardioembolic Ischemic Stroke.Journal of stroke · 2025Article
- Bleeding risk in East Asian patients with atrial fibrillation: Validation of the DOAC score in a Japanese multicenter registry.Heart rhythm O2 · 2025Article
- Enhanced clinical outcome and safety of Danhong injection combined with aspirin and clopidogrel for acute ischemic stroke: a retrospective study.American journal of translational research · 2025Article
- A retrospective analysis of e-prescriptions for non-communicable diseases on a telehealth platform in Malaysia.BMC health services research · 2024Observational
- The association between abcb1 gene polymorphism and clopidogrel response variability in stroke ischemic: a cross sectional study.BMC neurology · 2024Article
- Ethnic and Gender Variations in Ischemic Stroke Patterns among Arab Populations in Northern Israel: A Preliminary Exploration towards Culturally Aware Personalized Stroke Care.Journal of personalized medicine · 2024Article
- Article
- Dual Antiplatelet Therapy: A Concise Review for Clinicians.Life (Basel, Switzerland) · 2023Review
- Personalized Approaches to Antiplatelet Treatment for Cardiovascular Diseases: An Umbrella Review.Pharmacogenomics and personalized medicine · 2023Review
- Navigating Antiplatelet Treatment Options for Stroke: Evidence-Based and Pragmatic Strategies.Current neurology and neuroscience reports · 2022Review
- Aspirin Resistance in Vascular Disease: A Review Highlighting the Critical Need for Improved Point-of-Care Testing and Personalized Therapy.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThough combination of clopidogrel added to aspirin has been compared to aspirin alone in patients with stroke or transient ischemic attack, limited data exists on the relative efficacy and safety between clopidogrel and aspirin monotherapy in patients with a recent ischemic stroke. We aimed to compare clopidogrel versus aspirin monotherapy in this population.
methodsPubMed, Embase, and CENTRAL databases were searched from inception to May 2018 to identify clinical trials and observational studies comparing clopidogrel versus aspirin for secondary prevention in patients with recent ischemic stroke within 12 months. Pooled effect estimates were calculated using a random effects model and were reported as risk ratios with 95% confidence intervals.
resultsFive studies meeting eligibility criteria were included in the analysis. A total of 29,357 adult patients who had recent ischemic stroke received either clopidogrel (
conclusionsThe analysis showed lower risks of major adverse cardiovascular or cerebrovascular events, recurrent stroke, and bleeding events for clopidogrel monotherapy compared to aspirin. These findings support clinical benefit for single antiplatelet therapy with clopidogrel over aspirin for secondary prevention in patients with recent ischemic stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.